Literature DB >> 1723363

Therapeutic dilemmas in external ocular diseases.

P A Asbell1, M A Torres.   

Abstract

Three ocular conditions continue to pose therapeutic dilemmas for the practising clinician. Acanthamoeba keratitis, which presents with ocular pain, redness, tearing, photophobia and lid oedema, should be considered in any chronic, progressive corneal ulceration that is unresponsive to conventional treatment. Although the best treatment for this infection has yet to be defined, surgery should be reserved for those patients with progressive destructive disease or corneal penetration. Topical antibiotics and oral ketoconazole may be beneficial, as may surgical debridement in conjunction with topical antibiotic-antifungal combinations. However, since more than two-thirds of reported cases involve contact lens wearers, patients should be instructed as to the importance of regular lens care regimens. Giant papillary conjunctivitis occurs more frequently in soft contact lens wearers than in those wearing hard lenses, but may also occur in association with ocular prostheses, cataract surgery and corneal transplants. Symptoms of increased lens awareness, mucus accumulation, itching and blurred vision occur. Stopping use of contact lenses usually improves or eliminates these irritating effects, but is not always practical. Thus, resolution or improvement of symptoms while the patient continues to wear contact lenses is desirable, making lens hygiene essential in treatment. Pharmacological treatment includes the use of topical corticosteroids and agents that stabilise mast cells, such as cromolyn sodium. The dry eye syndrome can occur alone or as a part of Sjögren's syndrome. The irritation, redness, and other symptoms associated with ocular dryness are usually treated by preparations of either mucomimetics, polyvinyl alcohol or cellulose derivatives, which provide moisture and prevent evaporation from the surface of the eye.

Entities:  

Mesh:

Year:  1991        PMID: 1723363     DOI: 10.2165/00003495-199142040-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

1.  Giant papillary conjunctivitis in contact lens wearers.

Authors:  M R Allansmith; D R Korb; J V Greiner; A S Henriquez; M A Simon; V M Finnemore
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

Review 2.  Giant papillary conjunctivitis.

Authors:  M R Allansmith; R N Ross
Journal:  Int Ophthalmol Clin       Date:  1988

3.  Reaction to hydrophilic lenses.

Authors:  T F Spring
Journal:  Med J Aust       Date:  1974-03-23       Impact factor: 7.738

4.  Staging of conjunctival squamous metaplasia by impression cytology.

Authors:  S C Tseng
Journal:  Ophthalmology       Date:  1985-06       Impact factor: 12.079

5.  Topical retinoid therapy for squamous metaplasia of various ocular surface disorders. A multicenter, placebo-controlled double-masked study.

Authors:  H K Soong; N F Martin; M D Wagoner; E Alfonso; S H Mandelbaum; P R Laibson; R E Smith; I Udell
Journal:  Ophthalmology       Date:  1988-10       Impact factor: 12.079

6.  Vein grafting in nasolacrimal system reconstruction.

Authors:  D B Soll
Journal:  Ophthalmic Surg       Date:  1983-08

7.  Osmolarity of tear microvolumes in keratoconjunctivitis sicca.

Authors:  J P Gilbard; R L Farris; J Santamaria
Journal:  Arch Ophthalmol       Date:  1978-04

8.  Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.

Authors:  R L Kaswan; M A Salisbury; D A Ward
Journal:  Arch Ophthalmol       Date:  1989-08

9.  Medical and surgical treatment of Acanthamoeba keratitis.

Authors:  E J Cohen; C J Parlato; J J Arentsen; G I Genvert; R C Eagle; M R Wieland; P R Laibson
Journal:  Am J Ophthalmol       Date:  1987-05-15       Impact factor: 5.258

Review 10.  Tear physiology and dry eyes.

Authors:  F J Holly; M A Lemp
Journal:  Surv Ophthalmol       Date:  1977 Sep-Oct       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.